Register to watch this free webinar on-demand. A link to watch the recording will then be emailed to you shortly after registration.
This MEGIN Masterclass is presented by Dr Stefan Rampp. “Epileptic seizure of approximately 30% of patients with focal epilepsy cannot be adequately controlled with pharmacotherapy. In such pharmacoresistant cases, epilepsy surgery is a viable therapy option. Depending on the specific etiology, up to 60-80% of patients become seizure free after surgery, although a significant number suffer from recurrent seizures within 2-5 years after the procedure. A deciding factor regarding successful surgery and long-term seizure freedom is the exact localization of the epileptic focus and its relationship to essential functional cortex in the vicinity. With its high sensitivity and accuracy, MEG provides crucial information to tailor epilepsy surgery and ultimately improve postoperative outcomes. The masterclass will provide an overview of the application and impact of MEG focus localization for presurgical evaluation. Current evidence is reviewed, illustrated with case examples and accompanied by recommendations for practical implementation. Furthermore, novel markers of the epileptic network and their potential significance for practical applications are briefly discussed.”
A joining link to watch the MEGIN Masterclass will then be emailed to you shortly after registration.
*MEGIN does not endorse any applications or treatments mentioned at this event. TRIUX™ neo is intended to non-invasively locate regions of epileptic activity within the brain and, in conjunction with other diagnostic data, in neurosurgical planning. All other applications are research in nature.
*By submitting your information to register for a Masterclass, MEGIN will use it to communicate with you regarding this event and other services.